Lansoprazole 30mg gastro-resistant capsules

Land: Vereinigtes Königreich

Sprache: Englisch

Quelle: MHRA (Medicines & Healthcare Products Regulatory Agency)

Wirkstoff:

Lansoprazole

Verfügbar ab:

DE Pharmaceuticals

ATC-Code:

A02BC03

INN (Internationale Bezeichnung):

Lansoprazole

Dosierung:

30mg

Darreichungsform:

Gastro-resistant capsule

Verabreichungsweg:

Oral

Klasse:

No Controlled Drug Status

Verschreibungstyp:

Valid as a prescribable product

Produktbesonderheiten:

BNF: 01030500

Gebrauchsinformation

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LANSOPRAZOLE 15 MG & 30 MG GASTRO-RESISTANT CAPSULES
Lansoprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any of the side effects, talk to your doctor or pharmacist
. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IN THIS LEAFLET
1.
What Lansoprazole Capsules is and what it is used for
2.
What you need to know before you take Lansoprazole Capsules
3.
How to take Lansoprazole Capsules
4.
Possible side effects
5.
How to store Lansoprazole Capsules
6.
Contents of the pack and other information
1.
WHAT LANSOPRAZOLE CAPSULES IS AND WHAT IT IS USED FOR
The active ingredient in Lansoprazole is lansoprazole, which is a
proton pump inhibitor. Proton pump
inhibitors reduce the amount of acid that your stomach makes.
Your doctor may prescribe Lansoprazole for the following indications:
•
Treatment of duodenal and stomach ulcer
•
Treatment of inflammation in your oesophagus (reflux oesophagitis)
•
Prevention of reflux oesophagitis
•
Treatment of heartburn and acid regurgitation
•
Treatment of infections caused by the bacteria Helicobacter pylori
when given in combination
with antibiotic therapy
•
Treatment or prevention of duodenal or stomach ulcer in patients
requiring continued NSAID
•
treatment (NSAID treatment is used against pain or inflammation)
•
Treatment of Zollinger-Ellison syndrome.
Your doctor may have prescribed Lansoprazole for another indication or
with a dose different from
that which is written in this information leaflet. Please follow your
doctor’s instructions for taking
your medicine.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE LANSOPRAZOLE CAP

Fachinformation

OBJECT 1
LANSOPRAZOLE 30MG GASTRO-RESISTANT CAPSULES
Summary of Product Characteristics Updated 31-May-2019 | Accord-UK Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Lansoprazole 30 mg Gastro-Resistant Capsules
2. Qualitative and quantitative composition
Each capsule contains 30 mg lansoprazole
Excipient with known effect:
Each 30 mg capsule contains 200.949 mg sucrose
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Lansoprazole 30 mg: opaque white cap and body capsules. Each capsule
contains white or almost white
spherical microgranules.
4. Clinical particulars
4.1 Therapeutic indications
• Treatment of duodenal and gastric ulcer
• Treatment of reflux oesophagitis
• Prophylaxis of reflux oesophagitis
• Eradication of _Helicobacter pylori _(_H. pylori_) concurrently
given with appropriate antibiotic therapy for
treatment of _H.pylori_-associated ulcers
• Treatment of NSAID-associated benign gastric and duodenal ulcers
in patients